Openbookopenbook
Equity
BioNTech SE(BNTX)
USD --+0.00%
Reward42Moderate
Risk51Moderate
📊75%Data
Thin -40% profit margin · Revenue down 24% YoY
BNTX
+0.0 · +0.00%
USD · NASDAQ
BioNTech SE | Healthcare
Earnings Deterioration
Market Cap:25.69Bn
ℹ️
Reward Rating
42
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
51
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BNTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: €130.18.

What is BioNTech SE?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.

BNTX · Verdict

Moderate reward · elevated risk

BNTX has limited near-term tailwinds — volatility and growth weigh on the model output.

Based on 88% data coverage

BNTX · Verdict

What’s working & what to watch

Watchouts 3

  • Volatility20/100

    Weak vs peers

  • Growth29/100

    Revenue -45.8% CAGR

  • Profitability44/100

    -40% net margin · -6% ROE

Model-based scoring. For information only — not financial advice.

What is BioNTech SE?

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 25.69B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (42)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap25.69B
P/E RatioN/A
Dividend YieldN/A
52 Week High124
52 Week Low79.52
Last AnnualDecember
IPO Date10/10/2019
IncorporatedUSA
Shares Outstanding253M
No. of Employees7,807
IndustryBiotechnology
ExchangeNASDAQ
Beta1.593
CurrencyUSD · Reports in EUR
Websitewww.biontech.de
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.